Hypertrophy common in older patients with port-wine stains

July 13, 2012
Hypertrophy common in older patients with port-wine stains
Hypertrophy is present in the majority of patients with port-wine stains who are over the age of 50 years, according to a study published online July 2 in the Journal of the American Academy of Dermatology.

(HealthDay) -- Hypertrophy is present in the majority of patients with port-wine stains (PWS) who are over the age of 50 years, according to a study published online July 2 in the Journal of the American Academy of Dermatology.

Anne Margreet van Drooge, M.D., from the University of Amsterdam, and colleagues retrospectively analyzed and clinical photographs of all patients with PWS visiting a clinic between 2005 and 2009. Three hundred thirty-five participants (age range, 0 to 81 years; 69 percent female) responded to a questionnaire regarding hypertrophic PWS.

The researchers identified in 20 percent of PWS patients, which was classified as thickened (5 percent), nodular (8 percent), or both (7 percent). The color of hypertrophic PWS was mainly red or purple (50 and 44 percent, respectively). Sixty-eight percent of patients with hypertrophy in their PWS were older than 40 and only 7 percent were younger than 20 years. Of the patients older than 50 years, 71 percent had hypertrophy in their PWS. The of hypertrophy onset was 31 years -- 12 years for thickened hypertrophy and 39 years for nodular hypertrophy.

"This study shows that hypertrophy is a common development in PWS, affecting 20 percent of all patients with PWS and 71 percent of patients older than 50 years," the authors write. "Patients should be informed about the natural course of PWS and more attention needs to be drawn to therapy and prevention of hypertrophic PWS."

Explore further: Pulsed dye laser effective on port-wine stains in infants

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Pulsed dye laser effective on port-wine stains in infants

February 28, 2012
(HealthDay) -- Pulsed dye laser (PDL) treatment at two-, three-, and four-week intervals is effective for infants with facial port-wine stains (PWS), with minimal short-term side effects, according to a study published online ...

Risk of sudden cardiac death up for black patients with HTN

April 13, 2012
(HealthDay) -- Black patients with hypertension face a significantly increased risk of sudden cardiac death (SCD) compared with nonblack patients, even after adjusting for multiple confounding variables, according to a study ...

Recommended for you

Anti-malaria drug shows promise as Zika virus treatment

November 17, 2017
A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective ...

Decrease in sunshine, increase in Rickets

November 17, 2017
A University of Toronto student and professor have teamed up to discover that Britain's increasing cloudiness during the summer could be an important reason for the mysterious increase in Rickets among British children over ...

Scientists identify biomarkers that indicate likelihood of survival in infected patients

November 17, 2017
Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease.

Research team unlocks secrets of Ebola

November 16, 2017
In a comprehensive and complex molecular study of blood samples from Ebola patients in Sierra Leone, published today (Nov. 16, 2017) in Cell Host and Microbe, a scientific team led by the University of Wisconsin-Madison has ...

Study raises possibility of naturally acquired immunity against Zika virus

November 16, 2017
Birth defects in babies born infected with Zika virus remain a major health concern. Now, scientists suggest the possibility that some women in high-risk Zika regions may already be protected and not know it.

A structural clue to attacking malaria's 'Achilles heel'

November 16, 2017
Researchers from The Scripps Research Institute (TSRI) and PATH's Malaria Vaccine Initiative (MVI) have shed light on how the human immune system recognizes the malaria parasite though investigation of antibodies generated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.